30 September 2020
Advs. Micki Shapira, Daniel Green and Sophy Litvin represented Fosun Health Fund (the venture capital arm of Fosun Pharma) in an exclusive license and supply agreement with Raziel Therapeutics to develop and commercialize Raziel's proprietary RZL-012, an injection used for reducing double chins, in mainland China, Hong Kong, Macau, and Taiwan for milestone payments of up to $74 million plus tiered royalties on future sales. The team was joined by advs. Miriam Friedmann, Inbar Hakimian-Nahari and intern Yang Cheng.

Advs. Micki Shapira, Daniel Green and Sophy Litvin represented Fosun Health Fund (the venture capital arm of Fosun Pharma) in an exclusive license and supply agreement with Raziel Therapeutics to develop and commercialize Raziel's proprietary RZL-012, an injection used for reducing double chins, in mainland China, Hong Kong, Macau, and Taiwan for milestone payments of up to $74 million plus tiered royalties on future sales. The team was joined by advs. Miriam Friedmann, Inbar Hakimian-Nahari and intern Yang Cheng.


31 May 2020
英特尔以10亿美金收购Moovit公司 英特尔收购以色列导航应用开发商类似于谷歌2013年收购Waze导航应用开发商

英特尔以10亿美金收购Moovit公司

英特尔收购以色列导航应用开发商类似于谷歌2013年收购Waze导航应用开发商


25 September 2017

Yigal Arnon & Co. represented China International Capital Corporation, Hong Kong Securities Limited and Jefferies Hong Kong Limited, in the initial public offering of Sisram Medical

Advs. Simon Weintraub and Daniel Green represented China International Capital Corporation Hong Kong Securities Limited and Jefferies Hong Kong Limited, the joint sponsors (underwriters) in connection with the initial public offering of Sisram Medical – the first Israeli company to list on the Hong Kong Stock Exchange. The global offering of Sisram’s shares raised approximately US $112 million. Sisram Medical, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., had previously acquired Alma Lasers Ltd., an international company headquartered in Israel and a global leader in the field of energy-based systems for the aesthetic and surgical markets. In addition, our firm was involved in the process of having the State of Israel recognized as an “accepted jurisdiction” by the HKSE which will hopefully lead to future opportunities for Israeli companies seeking to list their shares on the Hong Kong Stock Exchange. 

Advs. Simon Weintraub and Daniel Green represented China International Capital Corporation Hong Kong Securities Limited and Jefferies Hong Kong Limited, the joint sponsors (underwriters) in connection with the initial public offering of Sisram Medical – the first Israeli company to list on the Hong Kong Stock Exchange. The global offering of Sisram’s shares raised approximately US $112 million. Sisram Medical, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., had previously acquired Alma Lasers Ltd., an international company headquartered in Israel and a global leader in the field of energy-based systems for the aesthetic and surgical markets.

In addition, our firm was involved in the process of having the State of Israel recognized as an “accepted jurisdiction” by the HKSE which will hopefully lead to future opportunities for Israeli companies seeking to list their shares on the Hong Kong Stock Exchange. 


14 February 2017
Daniel Green and Simon Weintraub participated in an article in the Medical Device Daily Magazine.

Daniel Green and Simon Weintraub participated in an article in the Medical Device Daily Magazine.


01 December 2015
Advs. Daniel Green and Eli Greenbaum represented Oramed Pharmaceuticals, an Israeli clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, in a licensing transaction with Hefei Tianhui Incubator of Technologies Co., Ltd., of China.  The agreement is worth $38 million, with future royalties, and gives HTIT exclusive rights to market Oramed’s oral insulin capsule, in China, Hong Kong and Macau.  This deal is alongside a $12 million equity investment in the company.  

Advs. Daniel Green and Eli Greenbaum represented Oramed Pharmaceuticals, an Israeli clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, in a licensing transaction with Hefei Tianhui Incubator of Technologies Co., Ltd., of China.  The agreement is worth $38 million, with future royalties, and gives HTIT exclusive rights to market Oramed’s oral insulin capsule, in China, Hong Kong and Macau.  This deal is alongside a $12 million equity investment in the company.  


Recognition

Subscribe for updates and news